White Pine Capital LLC acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) in the third quarter, Holdings Channel.com reports. The firm acquired 26,598 shares of the healthcare product maker’s stock, valued at approximately $2,629,000.
Several other hedge funds also recently bought and sold shares of ABT. Foresight Capital Management Advisors Inc. bought a new stake in Abbott Laboratories during the 3rd quarter worth approximately $31,000. Manning & Napier Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter valued at $31,000. Balance Wealth Partners LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at $34,000. Summit Securities Group LLC grew its position in shares of Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after purchasing an additional 118 shares in the last quarter. Finally, Addison Advisors LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at $40,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Insider Buying and Selling
In related news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the transaction, the executive vice president owned 100,791 shares in the company, valued at $11,691,756. This trade represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on ABT. Wells Fargo & Company increased their price objective on Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Wall Street Zen upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Argus cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. BTIG Research decreased their target price on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Finally, Robert W. Baird raised their price target on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.32.
Read Our Latest Research Report on Abbott Laboratories
Abbott Laboratories Stock Up 0.1%
Shares of ABT opened at $108.59 on Monday. The firm has a market cap of $188.08 billion, a P/E ratio of 40.52, a P/E/G ratio of 1.90 and a beta of 0.54. The stock has a 50 day simple moving average of $103.93 and a two-hundred day simple moving average of $101.74. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. The firm had revenue of $13.01 billion for the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The business’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $1.30 earnings per share. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
